ClinicalTrials.gg
CompletedNCT02264639Updated Jan 8, 2021Results posted

A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects With PNH

A Phase 1 interventional study of Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria (PNH), sponsored by Apellis Pharmaceuticals, Inc.. Completed at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-08.

Sponsored by Apellis Pharmaceuticals, Inc. (part of Biogen) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 68 studies in Hemoglobinuria, Paroxysmal with a site in United States — 10 open to participants now, 16 under way, 4 of them phase 3. Hemoglobinuria, Paroxysmal · United States.

Enrollment
48th of 54
9 · median 53
Started
2015
the only one that year
Phase 1
5 of 68
none open now
Registered
34th of 68
by date
Lead sponsor
3 of 68
Apellis Pharmaceuticals, Inc.

Among the 68 studies in Hemoglobinuria, Paroxysmal with a site in United States, this one is the 48th largest by enrollment of the 54 interventional ones that give a count, is the only one that started in 2015, is one of 5 in phase 1, and was the 34th registered.

Hemoglobinuria, Paroxysmal

191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.

Browse Hemoglobinuria, Paroxysmal studies →

Open to participants now

10 of the 68 studies in Hemoglobinuria, Paroxysmal with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 68 studies in Hemoglobinuria, Paroxysmal with a site in United States, or all of them as a file.
02

Study summary

This study will be the initial exploration of pegcetacoplan in patients with PNH. The assessments of the safety, tolerability, PK, and PD following administration of single and multiples doses of pegcetacoplan will guide decisions to further develop the drug.

03

Conditions studied

  • Paroxysmal Nocturnal Hemoglobinuria (PNH)

Keywords

  • PNH
  • Paroxysmal Nocturnal Hemoglobinuria
  • Complement inhibitor
  • Anemia
  • Hemoglobinuria
  • hematologic diseases
  • extravascular hemolysis (EVH)
  • intravascular hemolysis (IVH)
  • C3 inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or Female
  • At least 18 years of age
  • Weigh >55 kg
  • Diagnosed with PNH
  • On treatment with eculizumab (Soliris®) for at least 3 months
  • \< 10 g/dL at screening OR have received at least one transfusion within 12 months prior to screening
  • count of >30,000/mm3
  • > 500/mm3
  • Women of (WOCBP) must have a negative pregnancy test at screening and must agree to use protocol defined methods of for the duration of the study (see below)
  • Males with female partners of child bearing potential must agree to use protocol defined methods of contraception (see below) and agree to refrain from donating sperm for the duration of the study
  • Willing and able to give

Exclusion criteria

Exclusion Criteria:

  • Active bacterial infection
  • Known infection with , C or
  • Hereditary complement deficiency
  • History of bone marrow transplantation
  • Participation in any other drug trial or exposure to other investigational agent, device or procedure within 30 days
  • Evidence of prolongation defined as > 450 ms for males and > 470 ms for females at screening
  • (CrCl) \< 50 mL/min (Cockcroft-Gault formula) at screening
  • Breast-feeding women
  • History of meningococcal disease
  • No vaccination against N. meningitidis types A, C, W, Y and B (administered as two separate vaccinations), Pneumococcal conjugate vaccine or Pneumococcal polysaccharide vaccine 23 (PCV13 or PPSV23, respectively) and Haemophilus influenzae Type B (Hib) vaccination within 2 years prior to Day 1 (Visit 2) dosing.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    Cohort 1

    First Dose 25mg, Repeated Dose 5 mg/day

    Drug: Pegcetacoplan

  • Experimental
    Cohort 2

    First Dose 50 mg, Repeated Dose 30 mg/day

    Drug: Pegcetacoplan

  • Experimental
    Cohort 3

    Repeated Dose 180 mg/day

    Drug: Pegcetacoplan

  • Experimental
    Cohort 4

    Repeated Dose 270 mg/day

    Drug: Pegcetacoplan

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Treatment-Emergent Adverse Events (TEAEs), Including by Severity, During Single-dose Phase

    TEAEs were defined as AEs that developed or worsened after first dose of study drug (Day 1), and up to 30 days after last dose of study drug. The Investigator assessed AEs for severity and relatedness to study drug. AEs were graded according to the Common Terminology Criteria for Adverse Events (CTCAE, v4.03) based on: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Death related to AE.

    Time frame: From single dose of study drug (Day 1) up to 30 days

  2. Number of Subjects With TEAEs, Including by Severity, During Multiple-dose Phase

    TEAEs were defined as AEs that developed or worsened after first dose of study drug (Day 1), and up to 30 days after last dose of study drug. The Investigator assessed AEs for severity and relatedness to study drug. AEs were graded according to CTCAE, v4.03 based on: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Death related to AE.

    Time frame: From first dose of study drug up to 30 days after last dose of study drug (Cohorts 1-3: up to 58 days; Cohort 4: up to 759 days).

  3. Area Under the Curve (AUC) From Time 0 to the Last Measurable Concentration (AUC0-t) Over the Multiple Dosing Phase for Cohort 4

    Assessment of AUC0-t of pegcetacoplan over the multiple dosing phase, estimated using a non-compartmental approach and calculated by the linear-log trapezoidal method. Pegcetacoplan pharmacokinetic (PK) parameters were summarized for Cohort 4 only.

    Time frame: Blood samples for PK assessment were collected pre-dose and 4 hours post dose on Day 1 and pre-dose (trough) on Day 2 and up to Day 785.

  4. Maximum Pre-dose Serum Concentration (Ctrough,Max) Over the Multiple Dosing Phase for Cohort 4

    Assessment of Ctrough,max of pegcetacoplan over the multiple dosing phase, estimated using a non-compartmental approach. Pegcetacoplan PK parameters were summarized for Cohort 4 only. Ctrough,max was calculated for both 270 mg/day and 360 mg/day where subjects received both doses. Note: 1 subject in Cohort 4 who was receiving 360 mg/day was granted Sponsor and institutional review board approval to increase the dose further to the equivalent of 440 mg/day and Ctrough,max is also reported for this dose.

    Time frame: Blood samples for PK assessment were collected pre-dose and 4 hours post dose on Day 1 and pre-dose (trough) on Day 2 and up to Day 785.

07

Results

Posted Jan 8, 2021

Participant flow

Paroxysmal nocturnal hemoglobinuria (PNH) subjects who were still anemic during treatment with eculizumab (Soliris®) were enrolled in this Phase 1, open-label, single- and multiple-ascending dose study to receive treatment with pegcetacoplan (APL-2) as an add-on to standard of care treatment. The study was conducted at 7 sites in the United States.

Participant flow — Overall Study
MilestoneCohort 1 Single- and Multiple-dose PhaseCohort 2 Single- and Multiple-dose PhaseCohort 2 Single-dose Phase, Then Cohorts 2, 3, and 4 Multiple-dose PhaseCohorts 3 and 4 Multiple-dose PhaseCohort 4 Multiple-dose Phase
Started21114
Completed01013
Not completed20101
Withdrew: Death (after completing single-dose phase)10000
Withdrew: Withdrawal by subject (during multiple-dose phase)10000
Withdrew: Pregnancy (during multiple-dose phase)00100
Withdrew: Major intercurrent illness (during multiple-dose phase)00001

Outcome measures

PrimaryNumber of Subjects With Treatment-Emergent Adverse Events (TEAEs), Including by Severity, During Single-dose Phase

TEAEs were defined as AEs that developed or worsened after first dose of study drug (Day 1), and up to 30 days after last dose of study drug. The Investigator assessed AEs for severity and relatedness to study drug. AEs were graded according to the Common Terminology Criteria for Adverse Events (CTCAE, v4.03) based on: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Death related to AE.

Time frame:
From single dose of study drug (Day 1) up to 30 days
Reported as:
Count of participants · Participants
Number of Subjects With Treatment-Emergent Adverse Events (TEAEs), Including by Severity, During Single-dose Phase
ParticipantsCohort 1 Single-dose PhaseCohort 2 Single-dose Phase
Any TEAE12
TEAE at least possibly related to study drug01
Serious TEAE00
TEAE leading to study drug discontinuation00
TEAE leading to death00
Maximum severity of all TEAEs: mild01
Maximum severity of all TEAEs: moderate11
Maximum severity of all TEAEs: severe00
PrimaryNumber of Subjects With TEAEs, Including by Severity, During Multiple-dose Phase

TEAEs were defined as AEs that developed or worsened after first dose of study drug (Day 1), and up to 30 days after last dose of study drug. The Investigator assessed AEs for severity and relatedness to study drug. AEs were graded according to CTCAE, v4.03 based on: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Death related to AE.

Time frame:
From first dose of study drug up to 30 days after last dose of study drug (Cohorts 1-3: up to 58 days; Cohort 4: up to 759 days).
Reported as:
Count of participants · Participants
Number of Subjects With TEAEs, Including by Severity, During Multiple-dose Phase
ParticipantsCohort 1 Multiple-dose PhaseCohort 2 Multiple-dose PhaseCohort 3 Multiple-dose PhaseCohort 4 Multiple-dose Phase
Any TEAE1216
TEAE at least possibly related to study drug0114
Serious TEAE0002
TEAE leading to study drug discontinuation1000
TEAE leading to death0000
Maximum severity of all TEAEs: mild0010
Maximum severity of all TEAEs: moderate0202
Maximum severity of all TEAEs: severe1004
Maximum severity of all TEAEs: life-threatening0000
PrimaryArea Under the Curve (AUC) From Time 0 to the Last Measurable Concentration (AUC0-t) Over the Multiple Dosing Phase for Cohort 4

Assessment of AUC0-t of pegcetacoplan over the multiple dosing phase, estimated using a non-compartmental approach and calculated by the linear-log trapezoidal method. Pegcetacoplan pharmacokinetic (PK) parameters were summarized for Cohort 4 only.

Time frame:
Blood samples for PK assessment were collected pre-dose and 4 hours post dose on Day 1 and pre-dose (trough) on Day 2 and up to Day 785.
Reported as:
Mean · micrograms*hour/milliliter (μg*hour/mL)
Area Under the Curve (AUC) From Time 0 to the Last Measurable Concentration (AUC0-t) Over the Multiple Dosing Phase for Cohort 4
micrograms*hour/milliliter (μg*hour/mL)Cohort 4 Multiple-dose Phase
Area Under the Curve (AUC) From Time 0 to the Last Measurable Concentration (AUC0-t) Over the Multiple Dosing Phase for Cohort 46,500,000 ± 3,990,000
PrimaryMaximum Pre-dose Serum Concentration (Ctrough,Max) Over the Multiple Dosing Phase for Cohort 4

Assessment of Ctrough,max of pegcetacoplan over the multiple dosing phase, estimated using a non-compartmental approach. Pegcetacoplan PK parameters were summarized for Cohort 4 only. Ctrough,max was calculated for both 270 mg/day and 360 mg/day where subjects received both doses. Note: 1 subject in Cohort 4 who was receiving 360 mg/day was granted Sponsor and institutional review board approval to increase the dose further to the equivalent of 440 mg/day and Ctrough,max is also reported for this dose.

Time frame:
Blood samples for PK assessment were collected pre-dose and 4 hours post dose on Day 1 and pre-dose (trough) on Day 2 and up to Day 785.
Reported as:
Mean · μg/mL
Maximum Pre-dose Serum Concentration (Ctrough,Max) Over the Multiple Dosing Phase for Cohort 4
μg/mLCohort 4 Multiple-dose Phase
270 mg Dose627 ± 207
360 mg Dose543 ± 192
440 mg Dose624 ± NA

Adverse events

Collected over TEAE data is reported from first dose of study drug up to 30 days after last dose of study drug (Cohorts 1 and 2, single-dose phase: up to 30 days; Cohorts 1-3, multiple-dose phase: up to 58 days; Cohort 4, multiple-dose phase: up to 759 days).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1 Single-dose Phase1/2 (50%)0/2 (0%)1/2 (50%)
Cohort 2 Single-dose Phase0/2 (0%)0/2 (0%)2/2 (100%)
Cohort 1 Multiple-dose Phase0/1 (0%)0/1 (0%)1/1 (100%)
Cohort 2 Multiple-dose Phase0/2 (0%)0/2 (0%)2/2 (100%)
Cohort 3 Multiple-dose Phase0/2 (0%)0/2 (0%)1/2 (50%)
Cohort 4 Multiple-dose Phase0/6 (0%)2/6 (33.3%)6/6 (100%)
Most frequent serious events
Most frequent serious events
EventCohort 1 Single-dose PhaseCohort 2 Single-dose PhaseCohort 1 Multiple-dose PhaseCohort 2 Multiple-dose PhaseCohort 3 Multiple-dose PhaseCohort 4 Multiple-dose Phase
AnaemiaBlood and lymphatic system disorders0/20/20/10/20/21/6
Lower gastrointestinal haemorrhageGastrointestinal disorders0/20/20/10/20/21/6
PancreatitisGastrointestinal disorders0/20/20/10/20/21/6
Portal vein thrombosisHepatobiliary disorders0/20/20/10/20/21/6
SepsisInfections and infestations0/20/20/10/20/21/6
Alanine aminotransferase increasedInvestigations0/20/20/10/20/21/6
Aspartate aminotransferase increasedInvestigations0/20/20/10/20/21/6
Most frequent other events
Showing 10 of 106
Most frequent other events
EventCohort 1 Single-dose PhaseCohort 2 Single-dose PhaseCohort 1 Multiple-dose PhaseCohort 2 Multiple-dose PhaseCohort 3 Multiple-dose PhaseCohort 4 Multiple-dose Phase
Injection-site bruisingGeneral disorders0/20/20/12/21/24/6
Non-cardiac chest painGeneral disorders0/20/21/10/20/20/6
Vitamin B12 decreasedInvestigations0/20/21/10/20/20/6
HeadacheNervous system disorders0/20/21/10/20/25/6
DysaesthesiaNervous system disorders0/20/21/10/20/20/6
AnxietyPsychiatric disorders0/20/21/11/20/20/6
DepressionPsychiatric disorders0/20/21/10/20/20/6
Injection-site painGeneral disorders0/20/20/10/20/24/6
NauseaGastrointestinal disorders1/20/20/11/20/21/6
DiarrhoeaGastrointestinal disorders1/20/20/11/20/21/6

Baseline characteristics

The safety population included all enrolled subjects who received at least 1 dose of study drug. Total unique participants = 9. Subjects could participate in more than 1 cohort. 1 subject participated in Cohorts 2, 3 and 4, and 1 subject participated in Cohorts 3 and 4.

Age, Categorical
Age, Categorical(Participants)Cohort 1 Single- and Multiple-dose PhaseCohort 2 Single- and Multiple-dose PhaseCohort 2 Single-dose Phase, Then Cohorts 2, 3, and 4 Multiple-dose PhaseCohorts 3 and 4 Multiple-dose PhaseCohort 4 Multiple-dose PhaseTotal
<=18 years000000
Between 18 and 65 years111148
>=65 years100001
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1 Single- and Multiple-dose PhaseCohort 2 Single- and Multiple-dose PhaseCohort 2 Single-dose Phase, Then Cohorts 2, 3, and 4 Multiple-dose PhaseCohorts 3 and 4 Multiple-dose PhaseCohort 4 Multiple-dose PhaseTotal
Female201148
Male010001
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1 Single- and Multiple-dose PhaseCohort 2 Single- and Multiple-dose PhaseCohort 2 Single-dose Phase, Then Cohorts 2, 3, and 4 Multiple-dose PhaseCohorts 3 and 4 Multiple-dose PhaseCohort 4 Multiple-dose PhaseTotal
Hispanic or Latino000101
Not Hispanic or Latino211048
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1 Single- and Multiple-dose PhaseCohort 2 Single- and Multiple-dose PhaseCohort 2 Single-dose Phase, Then Cohorts 2, 3, and 4 Multiple-dose PhaseCohorts 3 and 4 Multiple-dose PhaseCohort 4 Multiple-dose PhaseTotal
American Indian or Alaska Native000000
Asian000000
Native Hawaiian or Other Pacific Islander000000
Black or African American000011
White211138
More than one race000000
Unknown or Not Reported000000
Region of Enrollment
Region of Enrollment(participants)Cohort 1 Single- and Multiple-dose PhaseCohort 2 Single- and Multiple-dose PhaseCohort 2 Single-dose Phase, Then Cohorts 2, 3, and 4 Multiple-dose PhaseCohorts 3 and 4 Multiple-dose PhaseCohort 4 Multiple-dose PhaseTotal
United States211149
08

Study locations

7 sites
  • University of Southern California Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
  • Lakes Research
    Miami Lakes, Florida 33014, United States
  • University of Lousiville
    Louisville, Kentucky 40202, United States
  • John Hopkins Hospital
    Baltimore, Maryland 21231, United States
  • Cure 4 The Kids Foundation
    Las Vegas, Nevada 89135, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2015 to primary completion in Oct 2018, 43 months.

Results were first posted in Jan 2021, 2 years 2 months after primary completion.

Of 19 phase 1 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 34. This study's 43 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2014
First posted
Oct 15, 2014
StartActual
Feb 23, 2015
Primary completionActual
Oct 22, 2018
CompletionActual
Oct 22, 2018
Results first posted
Jan 8, 2021
Last update
Jan 8, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02264639
Responsible party
Sponsor
First posted
Oct 15, 2014
Start date
Feb 23, 2015
Primary completion
Oct 22, 2018
Completion
Oct 22, 2018
Results posted
Jan 8, 2021
Last update
Jan 8, 2021

Study contacts

Federico Grossi, MD, PhD
study director · Apellis Pharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegcetacoplan

Start the discussion